Canaccord analyst Mark Massaro notes that Exact Sciences' shares are off following a short report published by Citron Research, and followed by a 1-on-1 appearance between the lead author of the short report and Kevin Conroy, Chairman and CEO of Exact Sciences. However, the analyst believes the author's short report to be flawed in several key areas, namely when it stated that "Colonoscopy is the gold standard" and is perfectly sensitive, "Exact Sciences will never be profitable," Medicare pricing will decline, Exact Sciences "terminal value might be $0," "Cologuard is not effective," and that there is no operating leverage. Massaro reiterates a Buy rating and $38 price target on the shares and says he is a buyer on weakness.